Wilserdly (giredestran)
- Region
- 🇺🇸 US
- Active substance
- giredestran
- Company
- Genentech Inc
- Status
- Approved
- FDA approval
- Mon 16 Nov 2026
- Designations
- New molecular entity
- Application
- NDA220791
- Official record
- www.accessdata.fda.gov
Regulatory milestones
FDA approves Wilserdly (giredestran), a new medicine
Genentech Inc; NDA220791; New molecular entity; capsule · source
In-depth analysis
Where it stands
Wilserdly (giredestran) is recorded as approved in the US. The FDA approval is dated 2026-11-16, and the sponsor is Genentech Inc. The official record describes it as a new medicine in capsule form.
The records do not give a therapeutic area or an indication. This analysis therefore cannot say what condition the product treats, which patients are eligible, or what dose and duration apply. Those details sit in the approved prescribing information, which is not part of the data provided.
No CHMP opinion date is recorded. The record covers only the US, and nothing indicates an EU filing or EU decision.
Regulatory pathway and designations
The approval is recorded under NDA220791, so the product went through a New Drug Application. The only designation listed is New molecular entity. In general FDA usage, that means the active ingredient had not previously been approved by the FDA, whether alone or in a combination.
The records list no expedited-program designations, such as priority review, breakthrough therapy, fast track or accelerated approval. They also give no orphan status, no review timeline and no PDUFA goal date. The absence of these entries in the records should not be read as confirmation that none applied.
Details such as the pivotal evidence, any advisory committee meeting, and any postmarketing requirements or commitments are likewise not in the records.
Safety and pharmacovigilance
The records contain no safety information, including no boxed warning, contraindications, REMS, or postmarketing safety commitments, so no assessment of the product's risk profile can be made from them.
What to watch
The first step is to read the FDA-approved label and review documents to confirm the indication, the population, the dosing, and any warnings or postmarketing study requirements. None of these are in the supplied records.
Beyond that, the records show no pending regulatory events. Possible follow-on events include a filing in other regions, such as an EMA submission leading to a CHMP opinion, but the records give no information on any such plans or timelines. Any outlook on these should wait for confirmation from official sources or the sponsor.
AI-generated on 2026-11-20 from the official records on this page (model claude-sonnet-5-5). It can contain errors: check the sources.
Follow Wilserdly
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.